title: Clinical and bacteriological profiles of patients with typhoid fever treated during 1975-1998 in the Tokyo Metropolitan Komagome Hospital.
abstract: Patients with typhoid fever presenting to the Tokyo Metropolitan Komagome Hospital during the period 1975-1998 were retrospectively investigated. All cases were diagnosed by a positive culture for Salmonella typhi in either of their clinical specimens. Of the total number of 130 patients, 57% contracted the disease abroad; this population increased in later years as the total numbers of cases decreased. The period from disease onset to diagnosis averaged 14 days with 20% of the cases requiring over three weeks to establish a diagnosis. As for symptomatology relative bradycardia was seen in less than half of the cases, and rose spots or splenomegaly in less than one third. A positive blood culture was the most frequent test establishing the diagnosis followed by a positive stool culture. Intestinal bleeding was recognized in as many as 35 cases (27%) and even intestinal perforation occurred in two cases (1.5%). Chloramphenicol was most commonly employed during the early study period, however, during the late period it was replaced by fluoroquinolones. The clinical cure rate was 98% with regimens that include fluoroquinolones/quinolone; however it was 87% with the other antimicrobial regimens. Bacteriological relapse occurred in 25% of the non-fluoroquinolone group while only in 2.0% in the fluoroquinolone/quinolone group. Four strains of Salmonella typhi that were multi-resistant to chloramphenicol, ampicillin and cotrimoxazole were isolated in travelers from Asia. Early diagnosis by appropriate bacteriological examination regardless of classical symptomatology should be stressed and the use of fluoroquinolones is warranted in the treatment of typhoid fever.
authors.affiliation: Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Japan. hoshiy01@gcrc.med.nyu.edu
authors.forename: Y
authors.initials: Y
authors.lastname: Hoshino
authors.forename: G
authors.initials: G
authors.lastname: Masuda
authors.forename: M
authors.initials: M
authors.lastname: Negishi
authors.forename: A
authors.initials: A
authors.lastname: Ajisawa
authors.forename: A
authors.initials: A
authors.lastname: Imamura
authors.forename: K
authors.initials: K
authors.lastname: Hachimori
authors.forename: N
authors.initials: N
authors.lastname: Takayama
authors.forename: T
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: M
authors.initials: M
authors.lastname: Kimura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002701:Chloramphenicol / Q000627:therapeutic use*; D005260:Female; D024841:Fluoroquinolones; D006786:Hospitals, Urban; D006801:Humans; D007223:Infant; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012485:Salmonella typhi / Q000302:isolation & purification*; D014435:Typhoid Fever / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000503:physiopathology
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D002701:Chloramphenicol